Compare Ascendis Pharma A/S (ASND) vs Garmin Ltd. (GRMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Garmin Ltd. — how do they compare? Ascendis Pharma A/S trades at $263 (market cap $17.74B), while Garmin Ltd. trades at $243.15 (market cap $46.89B). The key difference: Garmin Ltd. is far larger — about 2.6× Ascendis Pharma A/S's market cap, and Garmin Ltd. pays a 1.73% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | GRMN | |
|---|---|---|
Market Cap | $17.74B | $46.89B |
Sector | Health | Technology |
52-Week High | $277.18 | $267.52 |
52-Week Low | $163.32 | $187.10 |
Enterprise Value | $18.11B | $44.35B |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Garmin (GRMN) trades at $243.11, down 0.57% on the day, with a bullish technical signal supported by moving averages. The company shows strong fundamentals with 2025 revenue of $7.25B and net income of $1.66B, maintaining robust profitability margins. Recent product launches in aviation and marine electronics highlight ongoing innovation. The stock is near its consensus price target of $282.67, indicating potential upside from current levels.
The outlook for GRMN remains positive driven by consistent earnings beats and dividend stability, though valuation multiples appear elevated. Key risks include competitive pressures in consumer electronics and reliance on discretionary spending. Analyst sentiment is cautious with 74% hold ratings, suggesting balanced risk-reward near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →
